N,N-Dimethyl-3,4-methylendioxyphenylisopropylamin | 74698-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: N,N-Dimethyl-3,4-methylendioxyphenylisopropylamin
• 英文别名: 3,4-methylenedioxydimethylamphetamine；dl-3,4-methylenedioxydimethylamphetamine；MDDMA；N,N-Dimethyl-3,4-methylenedioxyamphetamine；1-(1,3-benzodioxol-5-yl)-N,N-dimethylpropan-2-amine
• CAS: 74698-50-3
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: JEJGUIDNYBAPGN-UHFFFAOYSA-N

物化性质

• 沸点：
  285.5±19.0 °C(Predicted)
• 密度：
  1.087±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于水中

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-Dimethyl-3,4-methylendioxyphenylisopropylamin 、 碘化钠 生成 1-(6-iodo-1,3-benzodioxol-5-yl)-N,N-dimethylpropan-2-amine
  参考文献：
  名称：

  GHAFFARI, M. A.;ALI, H.;ROUSSEAU, J.;VAN, LIER J. E., J. LABELL. COMPOUNDS AND RADIOPHARM., 26,(1989) C. 118-120

  摘要：

  DOI：
• 作为产物：
  描述：

  胡椒基丙酮 、 盐酸二甲胺 在 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 36.0h， 生成 N,N-Dimethyl-3,4-methylendioxyphenylisopropylamin
  参考文献：
  名称：

  3,4-亚甲基二氧基苯基异丙胺（3,4-亚甲基二氧基苯丙胺）的中枢活性N-取代类似物。

  摘要：

  3，4-亚甲基二氧基苯基异丙基胺及其N-甲基同系物的已知中枢神经系统活性促使合成一系列在氮原子上具有取代基的类似物。这些类似物的大多数（R =烷基，烯基，羟基，烷氧基和烷氧基烷基）是通过3,4-亚甲基二氧基苯基丙酮与适当的胺和氰基硼氢化钠进行还原性烷基化反应制备的。受阻异构体是间接合成的。在几种动物试验和人类受试者中对它们的药理活性的测量表明，中央活性随N取代基体积的增加而降低。

  DOI：

  10.1002/jps.2600690220

文献信息

• Modified release multi-layer tablet cannabinoid formulations
  申请人：CannTab Therapeutics, Limited

  公开号：US10772837B2

  公开（公告）日：2020-09-15

  The present invention provides modified release pharmaceutical compositions, and methods for administering the compositions to a user, including humans. The composition may contain a combination of ingredients in proportions calculated to achieve therapeutic effect, including at least the following ingredients: one or more natural or synthetic cannabinoids, one or more release modifying agent(s), and one or more pharmaceutically acceptable excipient(s). The composition may be in a multi-layered solid dosage form to provide fast, controlled and also sustained release of specific ingredients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. More specifically, the invention may control drug release in accordance with the therapeutic purpose and pharmacological properties of active substances.

  本发明提供了改良释放药物组合物，以及向使用者（包括人类）施用组合物的方法。组合物可包含按计算比例组合的成分以达到治疗效果，其中至少包括以下成分：一种或多种天然或合成大麻素、一种或多种释放调节剂和一种或多种药学上可接受的赋形剂。组合物可以是多层固体剂型，以提供特定成分的快速、可控和持续释放。更具体地说，本发明涉及包含大麻素的改良释放药物组合物及其制备工艺。更具体地说，本发明可根据治疗目的和活性物质的药理特性控制药物释放。
• Method for the detection of compounds comprising methylenedioxyphenyl and testing kit for the same
  申请人：Glattstein Baruch

  公开号：US20050130312A1

  公开（公告）日：2005-06-16

  Process and a test kit for the detection of drugs of methylenedioxy amphetamine family and derivatives, are disclosed. The process comprises (a) sampling sufficient amount of a material, suspected to be examined comprise of said methylenedioxyphenyl group; (b) admixing said sample with a sufficient amount of a strong acid reagent; and (c) detecting color gradual appearance and determining accordingly the presence of said methylenedioxy amphetamine drugs in predetermined interval of time. The test kit comprises a strong acid reagent; a color vs time chart comprising means for the detection of a specific drug by means of color and time of appearance, a reaction chamber wherein suspected material and said strong acid reagent are admixed and color is indicated; a sampler having means to collect sufficient amount of suspected material to be tested and to insert it to the reaction chamber.

  本发明公开了用于检测亚甲二氧基苯丙胺类药物及其衍生物的工艺和检测试剂盒。该工艺包括：(a) 取样足量的疑似由所述亚甲二氧基苯基组成的受检物质；(b) 将所述样品与足量的强酸试剂混合；(c) 在预定的时间间隔内检测逐渐出现的颜色，并据此确定是否存在所述亚甲二氧基苯丙胺类药物。检测试剂盒包括强酸试剂；颜色与时间对照表，包括通过颜色和出现时间检测特定药物的装置、反应室，在反应室中可疑物质与所述强酸试剂混合并显示颜色；采样器，具有收集足量待测可疑物质并将其插入反应室的装置。
• Braun; Shulgin; Braun, Arzneimittel-Forschung/Drug Research, 1980, vol. 30, # 5, p. 825 - 830
  作者：Braun、Shulgin、Braun

  DOI：——

  日期：——
• Antiparkinsonian Action of Phenylisopropylamines
  申请人：Caron G. Marc

  公开号：US20070027208A1

  公开（公告）日：2007-02-01

  A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease.
• Modified Release Multi-Layer Tablet Cannabinoid Formulations
  申请人：CannTab Therapeutics, Limited

  公开号：US20180263913A1

  公开（公告）日：2018-09-20

  The present invention provides modified release pharmaceutical compositions, and methods for administering the compositions to a user, including humans. The composition may contain a combination of ingredients in proportions calculated to achieve therapeutic effect, including at least the following ingredients: one or more natural or synthetic cannabinoids, one or more release modifying agent(s), and one or more pharmaceutically acceptable excipient(s). The composition may be in a multi-layered solid dosage form to provide fast, controlled and also sustained release of specific ingredients. More specifically, the invention relates to modified release pharmaceutical compositions comprising cannabinoids and a process for preparation thereof. More specifically, the invention may control drug release in accordance with the therapeutic purpose and pharmacological properties of active substances.